FCX
48
3
HON
64
4
PLD
45
-3
DOW
34
6
GRMN
59
7
BAC
62
5
AEP
54
-4
EW
41
4
NVDA
70
7
JNPR
60
2
FDX
62
8
TXT
82
7
XRX
59
2
IFF
48
6
LMT
62
2
XEL
62
-5
CAT
55
8
GOOG
51
5
GE
78
6
CL
50
2
FCX
48
3
HON
64
4
PLD
45
-3
DOW
34
6
GRMN
59
7
BAC
62
5
AEP
54
-4
EW
41
4
NVDA
70
7
JNPR
60
2
FDX
62
8
TXT
82
7
XRX
59
2
IFF
48
6
LMT
62
2
XEL
62
-5
CAT
55
8
GOOG
51
5
GE
78
6
CL
50
2
Financhill
Back

Ultragenyx Pharmaceutical Stock Predictions

Spencer Rascoff co-founded Zillow, scaling it to a $16B valuation. But everyday investors couldn't invest until the IPO, missing early gains.

This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.
Sell
35

RARE
Ultragenyx Pharmaceutical

Last Price:
$35.37
Seasonality Move:
11.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Missed investing in Uber? Don't Miss Mode.

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Ultragenyx Pharmaceutical Stock Forecast

  • Over the next 52 weeks, Ultragenyx Pharmaceutical has on average historically risen by 5.1% based on the past 11 years of stock performance.
  • Ultragenyx Pharmaceutical has risen higher in 5 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 45.45%
  • Is Ultragenyx Pharmaceutical Stock Undervalued?
    The current Ultragenyx Pharmaceutical [RARE] share price is $36.09. The Score for RARE is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
  • RARE is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.

Will Ultragenyx Pharmaceutical Stock Go Up Next Year?

  • Over the next 52 weeks, Ultragenyx Pharmaceutical has on average historically risen by 5.1% based on the past 11 years of stock performance.

Ultragenyx Pharmaceutical Stock Rating

Sell
35
Ultragenyx Pharmaceutical (RARE) is a Sell

Is Ultragenyx Pharmaceutical overpriced?

  • Ultragenyx Pharmaceutical has risen higher in 5 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 45.45%

Ultragenyx Pharmaceutical Stock Price History

Is RARE stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and RARE is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
ultragenyx.com

52-Week Data

52-Week High:
60.37
52-Week Low:
29.59

Prediction Charts

Market Cap:
3.4B
Price in USD:
36.09
Volume:
1.4M
Beta:
1.11

Technical Analysis

SMA50:
37.23
SMA100:
40.24
SMA200:
46.16
52-Wk Change:
-11.76%

Stock Predictions

  • Is Ultragenyx Pharmaceutical stock public?
    Yes, Ultragenyx Pharmaceutical is a publicly traded company.
  • What is the Ultragenyx Pharmaceutical stock quote today?
    The Ultragenyx Pharmaceutical stock price is 36.09 USD today.
  • How to buy Ultragenyx Pharmaceutical stock online?
    You can buy Ultragenyx Pharmaceutical shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Apr-23 36.90 37.31 37.81 36.15
Apr-24 37.43 37.64 37.85 37.01
Apr-25 37.45 38.09 38.15 36.92
Apr-28 38.40 37.98 38.90 37.49
Apr-29 37.97 38.07 38.44 37.67
Apr-30 37.80 38.98 39.24 37.80
May-1 39.00 38.97 39.25 37.89
May-2 39.20 39.30 40.13 39.18
May-5 39.24 38.87 39.42 38.54
May-6 38.00 35.06 38.39 34.96
May-7 35.66 33.42 36.03 32.76
May-8 33.13 35.98 36.85 33.13
May-9 36.31 35.11 37.50 35.01
May-12 36.93 36.09 37.28 35.96

Ultragenyx Pharmaceutical Earnings

Ultragenyx Pharmaceutical Earnings Report: Per Share Ultragenyx Pharmaceutical Earnings Q1 Q2 Q3 and Q4 last year and next year.

Ultragenyx Pharmaceutical Forecast Revenue Growth

Ultragenyx Pharmaceutical Stock Analysis: Historical quarterly revenues per share for Ultragenyx Pharmaceutical and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.16 per share, an increase next quarter of $0.37 per share, an increase this year of $0.86 per share, and an increase next year of $1.99 per share.

* Ultragenyx Pharmaceutical stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.